Navigation Links
AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
Date:6/25/2013

IRVINE, Calif., June 25, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001.  The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

"There is a significant unmet need for effective and well-tolerated agents in the treatment of both atherosclerosis and lipid modulation," said Thomas W. Gardner, Chairman and Chief Executive Officer of AtheroNova.  "Based on AHRO-001's preclinical profile, we believe it has the potential to offer patients effective treatment for these chronic conditions with an improved therapeutic profile.  We look forward to assessing AHRO-001 in human trials and are extremely pleased to have met a significant milestone with transitioning into a clinical stage company."

The Phase 1 study is a randomized, double-blind, placebo controlled study that assesses ascending doses of AHRO-001 in healthy adult volunteers.  The program advanced into Phase 1 clinical testing following extensive successful preclinical studies with AHRO-001.

"This is clearly an exciting and transformative time for us," remarked Mark K. Wedel, MD, Chief Medical Officer of AtheroNova.

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AtheroNova has shown positive results in animal models for regression of pl
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AtheroNova Announces Milestone Filing of IND in Russian Federation
2. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
5. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
6. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
7. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
8. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
9. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
10. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
11. Romark Laboratories Initiates Phase 3 Trial of New Influenza Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
(Date:11/22/2014)... MEDITE Group acquired by CytoCore, Inc. (OTCBB: CYOE) ... rd quarter sales ended September 30, 2014 of $8.7 ... nine months ended September 2014 and a $38,000 loss for ... quarter is usually a seasonable weak period due to ... for many countries worldwide, we are proud to announce record ...
(Date:11/21/2014)...  Alere Inc. (NYSE: ALR ), a ... Juliet Cunningham as Vice President, Investor Relations. In ... driving communications with the investment community. "As ... to increase shareholder value, it is critical that we ... Chief Executive Officer. "We are delighted that Juliet ...
Breaking Medicine Technology:CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3Alere Appoints Juliet Cunningham to Lead Investor Relations 2
... ATLANTA, Nov. 5, 2010 Cimzia® (certolizumab ... moderate to severe rheumatoid arthritis (RA) symptoms, reducing disease ... during the American College of Rheumatology,s 2010 Annual Scientific ... indicated for the treatment of adult patients with moderately ...
... Dendreon Corporation (Nasdaq: DNDN ) today announced that ... Conference, Phoenix, AZ on November 11, 2010 at 1:30 p.m. ... and available for replay from Dendreon,s website, www.dendreon.com . ... it will be archived on the site following the presentation. ...
Cached Medicine Technology:Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 2Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 3Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 4Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 5Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 6Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 7Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 8Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 9Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 10
(Date:11/23/2014)... 2014 SWAccessControl.com's high quality access control ... the company has announced its new collection of power ... these high quality power suppliers. All the new models ... special offer lasts until Dec. 20, 2014. , SWAccessControl.com ... have been supporting it for a long time. It ...
(Date:11/23/2014)... Beach, CA (PRWEB) November 23, 2014 ... of American Medical Aesthetics & Wellness was recently ... Asher Milgrom, Ph.D. is president and CEO of American ... Dr. Asher Milgrom received a full scholarship to ... and the Medical School at the University of Chicago, ...
(Date:11/23/2014)... 23, 2014 Syngenta lawsuits are now ... of farmers and agribusinesses that have allegedly incurred significant ... Agrisure Viptera and Agrisure Duracade, genetically modified (GMO) ... for sale in China. According to a report from ... ban U.S. corn imports. Because China is the third-largest ...
(Date:11/23/2014)... Lake City, Utah (PRWEB) November 23, 2014 ... individual health insurance reimbursement for small businesses, announced ... new book, The End of Employer-Provided Health Insurance. ... health insurance is the greatest financial risk facing ... challenge facing U.S. employers, small and large, when ...
(Date:11/22/2014)... November 23, 2014 Cancer researchers in ... connection between intercellular communication tunnels and the growth and ... full story on the Surviving Mesothelioma website. ... the University of Minnesota have just released their study ... and materials between cells. They found that mesothelioma ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2
... Veterinary Medical,Association (AVMA) today cited the release of ... Inspector General (OIG) report on pre-slaughter,activities in U.S. ... of,food animal veterinarians,( http://www.avma.org/press/releases/080208_nvmsa.asp ) can have dire,consequences ... The OIG report, which was released ...
... access from Internet fraud, Vetted International has implemented a higher level ... ... Raleigh, NC (PRWEB) December xx, 2008 --- Vetted Internationals ... from web fraud . An application upgrade to its ...
... says lack of exposure could also perpetuate more allergies ... Peanut and other food allergies are on the rise, ... life-threatening allergies, and schools are responding by providing nut-free ... schools are going too far, even creating hysteria over ...
... Obama,Administration sets its sights on stabilizing and strengthening ... today called on the transition,team and incoming Treasury ... where action by the Treasury Department is needed ... alcohol content,per serving and the definition of moderate, ...
... than 200 underprivileged,children in Detroit will receive new winter jackets ... annual Holiday Party presented by the Wayne County,Medical Society Foundation ... The New Detroit Science Center at 5020 John R at ... Physicians, medical students, physician spouses and staff ...
... Mich.Dec. 12 The Michigan Legislature,took an important step ... yesterday,by passing House Bill 4146, according to the Michigan ... The bill, introduced by Rep. Frank Accavitti (D-Eastpointe), regulates,tanning ... 18, larger warning signs in tanning facilities listing potential ...
Cached Medicine News:Health News:AVMA Calls for Increased Veterinary Oversight in Meat Production; Cites USDA Audit Report Initiated After Hallmark/Westland Recall 2Health News:AVMA Calls for Increased Veterinary Oversight in Meat Production; Cites USDA Audit Report Initiated After Hallmark/Westland Recall 3Health News:To Further Combat Internet Fraud, Heightened Security Levels are Implemented by Vetted International 2Health News:To Further Combat Internet Fraud, Heightened Security Levels are Implemented by Vetted International 3Health News:Nut Bans in Schools May Be Spurring Hysteria 2Health News:Nut Bans in Schools May Be Spurring Hysteria 3Health News:Consumer/Health Groups Call for Meaningful Change in How Treasury Department Regulates Alcohol Labeling 2Health News:Consumer/Health Groups Call for Meaningful Change in How Treasury Department Regulates Alcohol Labeling 3Health News:Consumer/Health Groups Call for Meaningful Change in How Treasury Department Regulates Alcohol Labeling 4Health News:Consumer/Health Groups Call for Meaningful Change in How Treasury Department Regulates Alcohol Labeling 5Health News:Consumer/Health Groups Call for Meaningful Change in How Treasury Department Regulates Alcohol Labeling 6Health News:Dermatologists Applaud Passage of Tanning Salon Regulation 2
... Designed for High Throughput Screening (HTS), ... assays into HTS by sharing all ... of Analyst AD, fluorescence intensity, fluorescence ... Optimized for seamless integration into robotic ...
... highly sensitive time-resolved fluorescence detection by ... These compounds are excited with the ... lifetimes (several hundred microseconds), large Stoke's ... at 620 nm. Therefore with the ...
... most advanced multi-functional microplate detection system, ... performance without compromising flexibility. ,The ... on the Ultra instrument platform. New ... adds to the flexibility of the ...
... is a fully automated microplate based ... measurement principles:, , Fluorescence Polarization ... , High-Performance Luminescence (flash and ... ,It is designed for the widest ...
Medicine Products: